Strategic Partnership Vibalogics is now part of Recipharm and recently announced a collaboration with Fusix Biotech to advance next‑generation cancer immunotherapies using oncolytic virus technology, signaling potential for co‑development and extended manufacturing partnerships in virotherapy.

Virotherapy Expertise As a full‑service CDMO with GMP cell and viral banking, process development, fill‑finish, and analytics, Vibalogics presents a one‑stop solution for early to late‑stage virotherapy programs, offering a compelling option for clients seeking end‑to‑end manufacturing support.

Global Compliance A foundation built on robust quality systems and regulatory compliance positions Vibalogics as a trustworthy partner for international virotherapy programs, reducing time‑to‑scale concerns for sponsors navigating global markets.

Diverse Product Experience Experience with live viruses, viral vectors, gene therapies, vaccines, and multiple virus platforms (AAV, adenovirus, poxviruses, VSV, RSV, etc.) enables Vibalogics to support a broad range of immunotherapy and vaccine candidates, expanding potential use cases for prospective clients.

Growth and Outreach Revenue scale indicates a smaller, high‑growth CDMO with room to expand service capacity; target opportunities include investigators and biotech startups seeking GMP‑grade development, scale‑up, and fill‑finish for virotherapy programs within Recipharm’s broader network.